Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies.
Berlanga P, Pierron G, Lacroix L, Chicard M, Adam de Beaumais T, Marchais A, Harttrampf AC, Iddir Y, Larive A, Soriano Fernandez A, Hezam I, Chevassus C, Bernard V, Cotteret S, Scoazec JY, Gauthier A, Abbou S, Corradini N, André N, Aerts I, Thebaud E, Casanova M, Owens C, Hladun-Alvaro R, Michiels S, Delattre O, Vassal G, Schleiermacher G, Geoerger B. Berlanga P, et al. Cancer Discov. 2022 May 2;12(5):1266-1281. doi: 10.1158/2159-8290.CD-21-1136. Cancer Discov. 2022. PMID: 35292802 Free PMC article.
Personalized Medicine in Infant Population with Cancer: Pharmacogenetic Pilot Study of Polymorphisms Related to Toxicity and Response to Chemotherapy.
Urtasun A, Olivera GG, Sendra L, Aliño SF, Berlanga P, Gargallo P, Hervás D, Balaguer J, Juan-Ribelles A, Andrés MDM, Cañete A, Herrero MJ. Urtasun A, et al. Among authors: berlanga p. Cancers (Basel). 2023 Feb 23;15(5):1424. doi: 10.3390/cancers15051424. Cancers (Basel). 2023. PMID: 36900216 Free PMC article.
Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.
Moreno L, Casanova M, Chisholm JC, Berlanga P, Chastagner PB, Baruchel S, Amoroso L, Gallego Melcón S, Gerber NU, Bisogno G, Fagioli F, Geoerger B, Glade Bender JL, Aerts I, Bergeron C, Hingorani P, Elias I, Simcock M, Ferrara S, Le Bruchec Y, Slepetis R, Chen N, Vassal G. Moreno L, et al. Among authors: berlanga p. Eur J Cancer. 2018 Sep;100:27-34. doi: 10.1016/j.ejca.2018.05.002. Epub 2018 Jun 21. Eur J Cancer. 2018. PMID: 29936064 Clinical Trial.
Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ network.
Bompas E, Martin V, Meniai F, Toulmonde M, Marec-Berard P, Claude L, Ducimetiere F, Chargari C, Minard-Colin V, Corradini N, Laurence V, Piperno-Neumann S, Defachelles AS, Bernier V, Italiano A, Orbach D, Blay JY, Gaspar N, Berlanga P. Bompas E, et al. Among authors: berlanga p. Bull Cancer. 2021 Feb;108(2):163-176. doi: 10.1016/j.bulcan.2020.10.009. Epub 2021 Jan 14. Bull Cancer. 2021. PMID: 33455736 Review.
Recent advances in understanding osteosarcoma and emerging therapies.
Gaspar N, Marques da Costa ME, Fromigue O, Droit R, Berlanga P, Marchais A. Gaspar N, et al. Among authors: berlanga p. Fac Rev. 2020 Nov 26;9:18. doi: 10.12703/r/9-18. eCollection 2020. Fac Rev. 2020. PMID: 33659950 Free PMC article. Review.
Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).
Ferrari A, van Noesel MM, Brennan B, Zanetti I, Corradini N, Casanova M, Berlanga P, Merks JHM, Alaggio R, Schifflers S, Ramirez-Villar GL, Giraudo C, Burrieza GG, Safwat A, Bisogno G, De Salvo GL, Orbach D. Ferrari A, et al. Among authors: berlanga p. Lancet Child Adolesc Health. 2021 Aug;5(8):546-558. doi: 10.1016/S2352-4642(21)00159-0. Epub 2021 Jun 30. Lancet Child Adolesc Health. 2021. PMID: 34214481 Clinical Trial.
Clinical and molecular analysis of smoothened inhibitors in Sonic Hedgehog medulloblastoma.
Pereira V, Torrejon J, Kariyawasam D, Berlanga P, Guerrini-Rousseau L, Ayrault O, Varlet P, Tauziède-Espariat A, Puget S, Bolle S, Beccaria K, Blauwblomme T, Brugières L, Grill J, Geoerger B, Dufour C, Abbou S. Pereira V, et al. Among authors: berlanga p. Neurooncol Adv. 2021 Jul 7;3(1):vdab097. doi: 10.1093/noajnl/vdab097. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 34409296 Free PMC article.
First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial.
Morscher RJ, Brard C, Berlanga P, Marshall LV, André N, Rubino J, Aerts I, De Carli E, Corradini N, Nebchi S, Paoletti X, Mortimer P, Lacroix L, Pierron G, Schleiermacher G, Vassal G, Geoerger B. Morscher RJ, et al. Among authors: berlanga p. Eur J Cancer. 2021 Nov;157:268-277. doi: 10.1016/j.ejca.2021.08.010. Epub 2021 Sep 17. Eur J Cancer. 2021. PMID: 34543871 Clinical Trial.
64 results